LongBio

LongBio is committed to developing differentiated next-generation macromolecular antibodies in the field of autoimmune diseases. The company's R&D pipeline focuses on unmet clinical needs in the autoimmune space, with multiple candidates steadily advancing. Leveraging its technology platforms—Antibody Discovery Platform, Antibody Engineering Platform, and Process Development Platform—LongBio will continue to advance and expand its R&D pipeline, bringing more clinical benefits to patients.